Prescient Therapeutics Limited

ASX:PTX 株式レポート

時価総額:AU$31.4m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

Prescient Therapeutics 過去の業績

過去 基準チェック /06

Prescient Therapeuticsの収益は年間平均-17.6%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間12.4% 17.7%割合で 増加しています。

主要情報

-17.6%

収益成長率

10.8%

EPS成長率

Biotechs 業界の成長9.6%
収益成長率17.7%
株主資本利益率-34.3%
ネット・マージン-248.7%
前回の決算情報31 Dec 2023

最近の業績更新

更新なし

Recent updates

We Think Prescient Therapeutics (ASX:PTX) Can Afford To Drive Business Growth

Mar 12
We Think Prescient Therapeutics (ASX:PTX) Can Afford To Drive Business Growth

We're Not Very Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Rate

Nov 14
We're Not Very Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Rate

Companies Like Prescient Therapeutics (ASX:PTX) Are In A Position To Invest In Growth

Aug 01
Companies Like Prescient Therapeutics (ASX:PTX) Are In A Position To Invest In Growth

Shareholders Would Not Be Objecting To Prescient Therapeutics Limited's (ASX:PTX) CEO Compensation And Here's Why

Nov 22
Shareholders Would Not Be Objecting To Prescient Therapeutics Limited's (ASX:PTX) CEO Compensation And Here's Why

Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation

Oct 19
Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation

Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business

Jun 19
Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business

Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business

Feb 27
Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Prescient Therapeutics Limited's (ASX:PTX) CEO For Now

Nov 05
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Prescient Therapeutics Limited's (ASX:PTX) CEO For Now

We Think Prescient Therapeutics (ASX:PTX) Can Easily Afford To Drive Business Growth

Aug 26
We Think Prescient Therapeutics (ASX:PTX) Can Easily Afford To Drive Business Growth

Prescient Therapeutics (ASX:PTX) Is In A Good Position To Deliver On Growth Plans

May 08
Prescient Therapeutics (ASX:PTX) Is In A Good Position To Deliver On Growth Plans

Does Prescient Therapeutics' (ASX:PTX) CEO Salary Compare Well With The Performance Of The Company?

Jan 11
Does Prescient Therapeutics' (ASX:PTX) CEO Salary Compare Well With The Performance Of The Company?

収支内訳

Prescient Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

ASX:PTX 収益、費用、利益 ( )AUD Millions
日付収益収益G+A経費研究開発費
31 Dec 233-848
30 Sep 233-747
30 Jun 232-746
31 Mar 232-645
31 Dec 222-544
30 Sep 222-544
30 Jun 222-543
31 Mar 222-543
31 Dec 211-543
30 Sep 211-533
30 Jun 211-432
31 Mar 211-423
31 Dec 201-323
30 Sep 201-323
30 Jun 201-323
31 Mar 201-423
31 Dec 192-423
30 Sep 192-424
30 Jun 192-424
31 Mar 191-323
31 Dec 181-323
30 Sep 181-322
30 Jun 181-322
31 Mar 181-312
31 Dec 171-312
30 Sep 171-312
30 Jun 171-312
31 Mar 171-222
31 Dec 161-221
30 Sep 161-221
30 Jun 161-221
31 Mar 161-221
31 Dec 151-221
30 Sep 151-211
30 Jun 150-211
31 Mar 150-211
31 Dec 140-210
30 Sep 140-210
30 Jun 140-210
31 Mar 140-110
31 Dec 130-110
30 Sep 130010

質の高い収益: PTXは現在利益が出ていません。

利益率の向上: PTXは現在利益が出ていません。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: PTXは利益が出ておらず、過去 5 年間で損失は年間17.6%の割合で増加しています。

成長の加速: PTXの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: PTXは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -2.3% ) と比較することは困難です。


株主資本利益率

高いROE: PTXは現在利益が出ていないため、自己資本利益率 ( -34.25% ) はマイナスです。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘